Cargando…
Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder
Attention plays an essential role in supporting other cognitive functions and behavior, and disturbance of attention is one of the most common symptoms in major depressive disorder (MDD). Although treatment with venlafaxine for MDD symptoms has been shown to reduce deficits in cognition and emotion...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910055/ https://www.ncbi.nlm.nih.gov/pubmed/27306061 http://dx.doi.org/10.1038/srep28028 |
_version_ | 1782437940511637504 |
---|---|
author | Tian, Yanghua Du, Jing Spagna, Alfredo Mackie, Melissa-Ann Gu, Xiaosi Dong, Yi Fan, Jin Wang, Kai |
author_facet | Tian, Yanghua Du, Jing Spagna, Alfredo Mackie, Melissa-Ann Gu, Xiaosi Dong, Yi Fan, Jin Wang, Kai |
author_sort | Tian, Yanghua |
collection | PubMed |
description | Attention plays an essential role in supporting other cognitive functions and behavior, and disturbance of attention is one of the most common symptoms in major depressive disorder (MDD). Although treatment with venlafaxine for MDD symptoms has been shown to reduce deficits in cognition and emotion regulation, it remains unclear whether venlafaxine improves specific attentional functions. We used the Attention Network Test to measure the attentional functions of alerting, orienting, and executive control before and after treatment with venlafaxine in patients with MDD compared to untreated healthy controls. Before treatment, the MDD group showed a selective impairment in alerting and executive control of attention, while there were no significant group differences in the orienting function. The interaction between group and session was significant for executive control, and after treatment with venlafaxine, the performance of the MDD group on executive control of attention was not significantly different from that of controls. Reported symptoms of MDD were also significantly reduced after treatment with venlafaxine. These results demonstrate that treatment with venlafaxine selectively normalizes the executive control function of attention in addition to improving clinical symptoms in MDD. |
format | Online Article Text |
id | pubmed-4910055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49100552016-06-16 Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder Tian, Yanghua Du, Jing Spagna, Alfredo Mackie, Melissa-Ann Gu, Xiaosi Dong, Yi Fan, Jin Wang, Kai Sci Rep Article Attention plays an essential role in supporting other cognitive functions and behavior, and disturbance of attention is one of the most common symptoms in major depressive disorder (MDD). Although treatment with venlafaxine for MDD symptoms has been shown to reduce deficits in cognition and emotion regulation, it remains unclear whether venlafaxine improves specific attentional functions. We used the Attention Network Test to measure the attentional functions of alerting, orienting, and executive control before and after treatment with venlafaxine in patients with MDD compared to untreated healthy controls. Before treatment, the MDD group showed a selective impairment in alerting and executive control of attention, while there were no significant group differences in the orienting function. The interaction between group and session was significant for executive control, and after treatment with venlafaxine, the performance of the MDD group on executive control of attention was not significantly different from that of controls. Reported symptoms of MDD were also significantly reduced after treatment with venlafaxine. These results demonstrate that treatment with venlafaxine selectively normalizes the executive control function of attention in addition to improving clinical symptoms in MDD. Nature Publishing Group 2016-06-16 /pmc/articles/PMC4910055/ /pubmed/27306061 http://dx.doi.org/10.1038/srep28028 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Tian, Yanghua Du, Jing Spagna, Alfredo Mackie, Melissa-Ann Gu, Xiaosi Dong, Yi Fan, Jin Wang, Kai Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder |
title | Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder |
title_full | Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder |
title_fullStr | Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder |
title_full_unstemmed | Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder |
title_short | Venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder |
title_sort | venlafaxine treatment reduces the deficit of executive control of attention in patients with major depressive disorder |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4910055/ https://www.ncbi.nlm.nih.gov/pubmed/27306061 http://dx.doi.org/10.1038/srep28028 |
work_keys_str_mv | AT tianyanghua venlafaxinetreatmentreducesthedeficitofexecutivecontrolofattentioninpatientswithmajordepressivedisorder AT dujing venlafaxinetreatmentreducesthedeficitofexecutivecontrolofattentioninpatientswithmajordepressivedisorder AT spagnaalfredo venlafaxinetreatmentreducesthedeficitofexecutivecontrolofattentioninpatientswithmajordepressivedisorder AT mackiemelissaann venlafaxinetreatmentreducesthedeficitofexecutivecontrolofattentioninpatientswithmajordepressivedisorder AT guxiaosi venlafaxinetreatmentreducesthedeficitofexecutivecontrolofattentioninpatientswithmajordepressivedisorder AT dongyi venlafaxinetreatmentreducesthedeficitofexecutivecontrolofattentioninpatientswithmajordepressivedisorder AT fanjin venlafaxinetreatmentreducesthedeficitofexecutivecontrolofattentioninpatientswithmajordepressivedisorder AT wangkai venlafaxinetreatmentreducesthedeficitofexecutivecontrolofattentioninpatientswithmajordepressivedisorder |